tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

ITOS Stock Latest News

iTeos Therapeutics: Poised for Success with Anti-TIGIT Therapies Amidst Competitive Landscape
RatingsiTeos Therapeutics: Poised for Success with Anti-TIGIT Therapies Amidst Competitive Landscape
1M ago
ITOS
iTeos Therapeutics price target lowered to $17 from $19 at Wells Fargo
PremiumThe Fly
iTeos Therapeutics price target lowered to $17 from $19 at Wells Fargo
1M ago
ITOS
Promising Developments and Strategic Updates Drive Buy Rating for iTeos Therapeutics
PremiumRatings
Promising Developments and Strategic Updates Drive Buy Rating for iTeos Therapeutics
1M ago
ITOS
iTeos Therapeutics: Undervalued with Promising Pipeline and Strong Financial Position
PremiumRatings
iTeos Therapeutics: Undervalued with Promising Pipeline and Strong Financial Position
1M ago
ITOS
iTeos Therapeutics reports Q4 EPS ($1.01), consensus ($1.02)
PremiumThe Fly
iTeos Therapeutics reports Q4 EPS ($1.01), consensus ($1.02)
1M ago
ITOS
iTeos Therapeutics Plans 2025 Data Presentation on Therapies
PremiumCompany AnnouncementsiTeos Therapeutics Plans 2025 Data Presentation on Therapies
3M ago
8K
ITOS
iTeos Therapeutics outlines business updates, strategies for 2025
Premium
The Fly
iTeos Therapeutics outlines business updates, strategies for 2025
3M ago
ITOS
iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo
Premium
The Fly
iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo
4M ago
ITOS
iTeos Therapeutics price target lowered to $21 from $46 at H.C. Wainwright
PremiumThe Fly
iTeos Therapeutics price target lowered to $21 from $46 at H.C. Wainwright
4M ago
ITOS
iTeos Therapeutics presents interim A2A-005 clinical trial data
PremiumThe Fly
iTeos Therapeutics presents interim A2A-005 clinical trial data
4M ago
ITOS
iTeos Therapeutics Reports Q3 2024 Financial Results
PremiumCompany Announcements
iTeos Therapeutics Reports Q3 2024 Financial Results
5M ago
ITOS
iTeos Therapeutics reports Q3 EPS ($1.05), consensus (89c)
PremiumThe Fly
iTeos Therapeutics reports Q3 EPS ($1.05), consensus (89c)
5M ago
ITOS
Officina Stellare Secures €1.4 Million Satellite Contract
PremiumCompany AnnouncementsOfficina Stellare Secures €1.4 Million Satellite Contract
5M ago
ITOS
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
7M ago
QS
ACB
Disney, DirecTV agree to restore programming, B+L mulls sale: Morning Buzz
Premium
The Fly
Disney, DirecTV agree to restore programming, B+L mulls sale: Morning Buzz
7M ago
C
T
iTeos Therapeutics participates in a conference call with JPMorgan
PremiumThe Fly
iTeos Therapeutics participates in a conference call with JPMorgan
7M ago
ITOS
Morning Movers: Bausch + Lomb surges as said to consider potential sale
PremiumThe Fly
Morning Movers: Bausch + Lomb surges as said to consider potential sale
7M ago
AAPL
ALOT
iTeos Therapeutics Reports Positive Phase 2 Cancer Trial Results
PremiumCompany Announcements
iTeos Therapeutics Reports Positive Phase 2 Cancer Trial Results
7M ago
8K
ITOS
iTeos Therapeutics announces follow-up interim data from GALAXIES Lung-201
PremiumThe Fly
iTeos Therapeutics announces follow-up interim data from GALAXIES Lung-201
7M ago
GSK
ITOS
iTeos Therapeutics initiated with an Overweight at Wells Fargo
PremiumThe FlyiTeos Therapeutics initiated with an Overweight at Wells Fargo
8M ago
ITOS
iTeos Therapeutics reports Q2 EPS (96c), consensus ($1.04)
Premium
The Fly
iTeos Therapeutics reports Q2 EPS (96c), consensus ($1.04)
8M ago
ITOS
iTeos Therapeutics appoints Feltquate as Chief Medical Officer
Premium
The Fly
iTeos Therapeutics appoints Feltquate as Chief Medical Officer
8M ago
ITOS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >